11669915001
Roche
Cell Proliferation ELISA, BrdU (chemiluminescent)
Synonym(s):
BrdU, cell proliferation
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
41116158
Recommended Products
usage
sufficient for ≤1,000 tests
Quality Level
manufacturer/tradename
Roche
technique(s)
ELISA: suitable
detection method
chemiluminescent
shipped in
wet ice
storage temp.
2-8°C
General description
Chemiluminescent immunoassay for the quantification of cell proliferation, based on the measurement of BrdU incorporation during DNA synthesis: a nonradioactive alternative to the [3H]-thymidine incorporation assay.
Specificity
The antibody conjugate reacts with the thymidine analogue 5-bromo-2′-deoxyuridine (BrdU) and with BrdU incorporated into DNA. For binding to BrdU incorporated into the DNA, the BrdU-labeled DNA has to be denatured. The antibody does not cross-react with any endogenous cellular components such as thymidine, uridine, or DNA.
Application
Cell Proliferation ELISA, BrdU (chemiluminescent) has been used:
- for bromodeoxyuridine (BrdU) proliferation assay in ReN and primary astrocytes
- to test the effect on imatinib on the proliferation of neuroblastoma cells using BrdU incorporation assay
- to check the effect of palbociclib on cell cycle inhibition using BrdU incorporation in pancreatic patient-derived primary cell lines
The Cell Proliferation ELISA, BrdU (chemiluminescent) belongs to the second, improved generation of kits for measuring DNA synthesis. It is a precise, fast, and simple nonradioactive alternative to quantitate cell proliferation based on the measurement of BrdU incorporation during DNA synthesis in replicating (cycling) cells. Thus, the Cell Proliferation ELISA can be used in many different in vitro cell systems. For example:
- Detection and quantification of cell proliferation induced by growth factors and cytokines
- Determination of the inhibitory or stimulatory effects of various compounds on cell proliferation in environmental and biomedical research, and in the food, cosmetic, and pharmaceutical industries
- Measurement of the immunoreactivity of lymphocytes, stimulated by mitogens or antigens
- Analysis of the chemosensitivity of tumor cells to different cytostatic drugs in medical research
Packaging
1 kit containing 7 components.
Components
- BrdU Labeling Reagent, 1,000x conc
- FixDenat
- Anti-BrdU-POD 4. Antibody Dilution Solution
- Washing Buffer PBS, 10x conc.
- Substrate Component A
- Substrate Component B
Other Notes
For life science research only. Not for use in diagnostic procedures.
Kit Components Only
Product No.
Description
- BrdU Labeling Reagent
- FixDenat ready-to-use
- Anti-BrdU-peroxidase antibody
- Antibody Dilution Solution ready-to-use
- ready-to-use 10x concentrated
- Substrate Component A
- Substrate Component B
Signal Word
Danger
Hazard Statements
Precautionary Statements
Hazard Classifications
Eye Irrit. 2 - Flam. Liq. 2 - Muta. 1B - Skin Sens. 1
Storage Class Code
3 - Flammable liquids
WGK
WGK 1
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Juliann E Kosovec et al.
Oncotarget, 8(59), 100421-100432 (2017-12-17)
Esophageal adenocarcinoma (EAC) is a deadly disease with limited therapeutic options. In the present study, we determined the preclinical efficacy of CDK4/6 inhibitor abemaciclib for treatment of EAC. In vitro, apoptosis, proliferation, and pathway regulation were evaluated in OE19, OE33
Xiao-Feng Wang et al.
Molecular medicine reports, 12(4), 5917-5923 (2015-08-25)
Epirubicin, an anthracycline derivative, is one of the main line treatments for brain tumors. The aim of the present study was to verify that epirubicin alters the growth and morphological characteristics of U‑87 glioma cells. In the present study, the
Valerio Ciccone et al.
Oncotarget, 9(17), 13353-13365 (2018-03-24)
Nitric oxide (NO) exerts conflicting effect on tumor growth and progression, depending on its concentration. We aimed to characterize the anti-cancer activity of a new NO donor, Ni(SalPipNONO) belonging to the class of metal-nonoates, in epithelial derived tumor cells, finally
Tino Schneider et al.
Glycobiology, 25(8), 812-824 (2015-04-17)
The present study demonstrates that fucose-containing sulfated polysaccharides (FCSP) from brown algae interfere with the CXCL12/CXCR4 axis in human Burkitt's lymphoma cells by binding CXCL12 and thereby blocking both CXCL12-induced CXCR4 receptor activation and downstream effects like migration and secretion
Elisa Lupino et al.
Biochemical pharmacology, 92(2), 235-250 (2014-09-30)
Imatinib mesylate is a tyrosine kinase inhibitor with selectivity for abelson tyrosine-protein kinase 1 (c-Abl), breakpoint cluster region (Bcr)-Abl fusion protein (Bcr-Abl), mast/stem cell growth factor receptor Kit (c-Kit), and platelet-derived growth factor receptor (PDGFR). Previous studies demonstrated that imatinib
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service